You are here

New Drug Application for Generic Equivalent of Unasyn Approved by FDA

SCHAUMBURG, Ill., Nov. 30 /PRNewswire-FirstCall/ -- American Pharmaceutical Partners, Inc. (NASDAQ:APPX) , today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for the combination drug Ampicillin and Sulbactam for Injection, USP, the generic equivalent of Pfizer Inc.'s Unasyn(R). Annual sales in 2004 of this product exceeded $116 million, of which $83 million was sold in vials, according to IMS. APP expects to commence marketing Ampicillin and Sulbactam immediately.

"The addition of Ampicillin and Sulbactam brings to 17 the number of generic anti-infective products in our portfolio and bolsters our industry leading position for these types of injectable products," said Patrick Soon-Shiong, M.D., chairman and chief executive officer. "Our ability to provide customers with a wide array of anti-infectives enabled us to have GPO contracts in place at launch."

Ampicillin and Sulbactam will be available from APP in 1.5g and 3g single dose vials (SDV). The product is preservative-free and AP rated and each vial will include a bar code and latex-free vial stopper. The approval is the fifth product approval APP has received this year.

Ampicillin and Sulbactam is an injectable antibacterial combination consisting of the seminsynthetic antibiotic ampicillin sodium and the beta-lactamase inhibitor sulbactam sodium. Administered intravenously or intramuscular, Ampicillin and Sulbactam is indicated for the treatment of several skin and skin structure, intra-abdominal and gynecological infections due to susceptible strains of microorganisms.

Source: American Pharmaceutical Partners

Recent Headlines

Lower court rulings cleared the way for generic versions of the MS drug
Maryland man wins lawsuit that alleges that the company's antipsychotic caused his gynecomastia
Antidepressants, ADHD meds are also used to self-poison
Scenesse is new treatment for people with rare, painful light sensitivity disease
Humira, Rituxan top list of drugs that added $5.1 billion to nation's health care bill
Study lists steps that could save close to $300 billion a year
While many victims used THC, the cause remains elusive
Descovy joins Truvada, another Gilead product, in the HIV prophylaxis market
Data show PTC Therapeutics drug preserves lung function